Monopar Therapeutics Inc. Quarterly report pursuant to Section 13 or 15(d)

Quarterly report pursuant to Section 13 or 15(d)

Note 3 - Investments

Note 3 - Investments

9 Months Ended

Sep. 30, 2023

Note 3 - Investments

As of September 30, 2023, the Company had two money market accounts recorded in cash and cash equivalents and available-for-sale investments with contractual maturities of one year or less as follows:

As of September 30, 2023	*Cost Basis*		*Unrealized Gains*		*Aggregate Fair Value*

U.S. Treasury Bills	$	4,944,340	$	18,300	$	4,962,640
Money Market Accounts - Cash Equivalents		2,687,463		—		2,687,463
Total	$	7,631,803	$	18,300	$	7,650,103

As of September 30, 2023, there were no available-for-sale securities in an unrealized-loss position. U.S. Treasury Bills classified as Investments on the condensed consolidated balance sheet as of September 30, 2023 were $3.0 million.

As of December 31, 2022 the Company had two money market accounts recorded in cash and cash equivalents and available-for-sale investments with contractual maturities of one year or less as follows:

As of December 31, 2022	Cost Basis		Unrealized Gains		Aggregate Fair Value

U.S. Treasury Bills	$	6,905,171	$	15,039	$	6,920,210
Money Market Accounts - Cash Equivalents		5,262,286		—		5,262,286
Total	$	12,167,457	$	15,039	$	12,182,496

As of December 31, 2022, there were no available-for-sale securities in an unrealized-loss position and there were no sales of available-for-sale securities made during 2022. U.S. Treasury Bills classified as Investments on the condensed consolidated balance sheet as of December 31, 2022 were $4.9 million.

See Note 2 for additional discussion regarding the Company’s fair value measurements.